natgillin/translations-raw huggingface dataset:
Remsima 120 mg solution for injection in pre-filled syringe with automatic needle guard Remsima 120 mg solution for injection in single-use pre-filled syringe with automatic needle guard. 
Zdravilo Remsima 120 mg raztopina za injiciranje v napolnjeni injekcijski brizgi za enkratno uporabo s samodejnim ščitnikom za iglo.
Do not use the pen if: 
Po potrebi namestite obliž.
• Some patients who have received TNF-blockers, including infliximab have developed a rare type of cancer called hepatosplenic T-cell lymphoma. 
• Pri nekaterih bolnikih, ki so prejemali zaviralce TNF, vključno z infliksimabom, se je pojavila redka oblika raka, ki mu pravimo hepatosplenični limfom celic T. Od teh bolnikov je bila večina najstnikov ali mladih moških in večina je imela Crohnovo bolezen ali ulcerozni kolitis.
In phase III clinical studies, 18% of infliximab-treated patients compared with 5% of placebo-treated patients experienced an infusion-related reaction. 
V kliničnih študijah faze III se je pri 18 % bolnikov,
• Side effect due to an infusion 
• neželeni učinek zaradi infuzije • bolečine.
At 
Bat
Concurrent use of stable doses of oral corticosteroids (≤10 mg/day) and/or NSAIDs was permitted, and folate supplementation was given. 
Sočasna uporaba stalnih odmerkov peroralnih kortikosteroidov (≤ 10 mg/dan)
Children who took infliximab for Crohn's disease showed some differences in side effects compared with adults who took infliximab for Crohn's disease. 
Dodatni neželeni učinki pri otrocih in mladostnikih Neželeni učinki pri otrocih in odraslih, ki so prejemali infliksimab za zdravljenje Crohnove bolezni, so se nekoliko razlikovali.
In one of the study arms (group 2, n=329), patients with an inadequate response were allowed to dose titrate with 1.5 mg/kg increments from 3 up to 9 mg/kg. 
(skupina 2, n=329) so bolnikom z nezadostnim odzivom na zdravilo omogočili titracijo t.j.
Date of Remsima therapy initiation: 
Zdravilo Remsima uporabljajte:
5 mg/kg given as an intravenous infusion followed by an additional 5 mg/kg infusion 2 weeks after the first infusion. 
Zmerno do močno aktivna Crohnova bolezen Odmerek je 5 mg/kg v obliki intravenske infuzije, čemur naj sledi dodatna infuzija v odmerku 5 mg/kg 2 tedna po prvi infuziji.
• Urinary tract infection 
• Injekcijski peresnik
In patients treated with infliximab, an invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they develop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of invasive fungal infections should be consulted at an early stage when investigating these patients. 
kokcidioidomikoza ali blastomikoza, poleg tega pa je pri teh bolnikih že zgodaj v poteku preiskav potreben posvet z zdravnikom, ki ima strokovno znanje iz diagnostike in zdravljenja invazivnih glivičnih okužb.
Each Remsima vial contains 100 mg infliximab. 
Remsima vsebuje 100 mg infliksimaba.
• Some patients receiving infliximab have developed serious liver problems. 
Težave z jetri • Pri nekaterih bolnikih, ki prejemajo zdravilo Remsima, so se pojavile resne težave z jetri.
Talk to your doctor before or during treatment with Remsima if you have: 
Pred ali med zdravljenjem z zdravilom Remsima, se v naslednjih primerih posvetujte z zdravnikom: Predhodno ste se že zdravili s katerim koli zdravilom, ki vsebuje infliksimab
Ελλάδα 
po NYHA).
The incidence of systemic injection reactions (e.g. rash, pruritus, flushing and oedema) was 1.2 per 100 patient-years in the Remsima subcutaneous group (from Week 6) and 2.1 per 100 patient-years in the Remsima intravenous group who switched to Remsima subcutaneous administration (from Week 30). 
V skupini, ki je prejemala zdravilo Remsima v intravenski obliki (od 6. tedna naprej) in ki je prešla na zdravilo Remsima v subkutani obliki (od 30. tedna naprej), je bila pojavnost sistemskih z injiciranjem povezanih reakcij (npr. izpuščaj, pruritus, rdečica in edem) 1,2 na 100 bolnikov-let in 2,1 na 100
Read carefully these instructions before using the Remsima pen. 
Pred uporabo injekcijskega peresnika z zdravilom Remsima natančno preberite ta navodila.
Package leaflet: Information for the user Remsima 100 mg powder for concentrate for solution for infusion infliximab 
Navodilo za uporabo Remsima 100 mg prašek za koncentrat za raztopino za infundiranje infliksimab
Remsima is however, diluted in sodium chloride 9 mg/ml (0.9%) solution for infusion. 
(0,9-%) raztopino natrijevega klorida za infundiranje.
Indication Number of patients2 Median follow-up (wks)3 
Indikacija Število bolnikov2
Before treatment with Remsima 
Pred zdravljenjem s tem zdravilom
• 1 prefilled syringe (1 mL sterile solution) with 2 alcohol pads. 
• 1 napolnjena injekcijska brizga (1 ml sterilne raztopine) z 2 alkoholnima zložencema.
The syringe inside the pen is made from type 1 glass with a plunger stopper (flurotec-coated elastomer) and needle with a rigid needle shield. 
Injekcijska brizga v injekcijskem peresniku je izdelana iz stekla tipa I z batnim zamaškom (iz elastomera s prevleko
Keep the pre-filled pen in its package in order to protect from light. 
Shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
The solution must not be used if opaque particles, discolouration, or other foreign particles are present. 
Raztopine ne smete uporabiti, če so prisotni neprosojni delci,
• 2 prefilled syringes (1 mL sterile solution) with 2 alcohol pads. 
• 2 napolnjeni injekcijski brizgi (1 ml sterilne raztopine) z 2 alkoholnima zložencema.
ACCENT II (Week-14 responders) 
ACCENT II (bolniki z odzivom v 14. tednu) Vzdrževalno zdravljenje s placebom (n = 99)
Vaginitis. 
Ohišje
b all infliximab doses given in combination with methotrexate and folate with some on corticosteroids and/or NSAIDs c p <0.001, for each infliximab treatment group vs. control d greater values indicate more joint damage. 
b Vsi odmerki infliksimaba so bili v kombinaciji z metotreksatom in folatom, nekaj tudi s kortikosteroidi in/ali NSAID.
No dose recommendations can be made (see section 5.2). 
Infliksimabom pri teh populacijah bolnikov niso proučevali, zato ni mogoče podati priporočil za odmerjanje (glejte poglavje 5.2).
Carriers of HBV who require treatment with infliximab should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. 
Pri tistih bolnikih, ki imajo pozitiven izvid na okužbo z virusom HBV, je priporočljiv tudi posvet z zdravnikom, ki ima izkušnje z zdravljenjem hepatitisa B. Prenašalce virusa HBV, ki potrebujejo zdravljenje z infliksimabom, je treba ves čas zdravljenja in še več mesecev po prekinitvi oz. zaključku zdravljenja skrbno spremljati, da pri njih ugotovite morebitne znake in simptome aktivne okužbe z virusom HBV. Ni zadostnih podatkov o zdravljenju prenašalcev virusa HBV s protivirusno terapijo ob uporabi zaviralec TNF za preprečevanje reaktivacije hepatitisa B. Pri bolnikih, pri katerih se ponovno aktivira okužba s HBV, je treba infliksimab ukiniti in uvesti učinkovito protivirusno terapijo z ustreznimi podpornimi ukrepi.
Moderately to severely active Crohn's disease 
Začetno zdravljenje pri aktivni Crohnovi bolezni s fistulami
Percentage of subjects with mucosal healing 
Odstotek preiskovancev s celjenjem sluznice
Conjunctivitis 
Odziv
SC 
Z
• 1 prefilled pen (1 mL sterile solution) with 2 alcohol pads. 
• 1 napolnjen injekcijski peresnik (1 ml sterilne raztopine) z 2 alkoholnima zložencema.
d p = 0.030 and <0.001 for the 3 mg/kg and 6 mg/kg treatment groups respectively vs. placebo + MTX. 
do 54. tednac Srednja vrednost ± SDd a p < 0,001 za vsako terapevtsko skupino, ki je prejemala infliksimab, v primerjavi s kontrolno skupino b večje vrednosti pomenijo večjo okvaro sklepov c HAQ = vprašalnik za oceno zdravstvenega stanja; večje vrednosti pomenijo manjšo okvaro sklepov d p = 0,030 in < 0,001 za terapevtski skupini, ki sta prejemali 3 mg/kg in 6 mg/kg v primerjavi s placebom + MTX
PASI 75 response** * ITT-analysis where subjects with missing data were included as non-responders. 
PASI 75** * Analiza namere zdravljenja (ITT), v kateri so preiskovance brez nekaterih podatkov šteli med neodzivne bolnike a Podatki za 98. teden iz študije IMPACT vključujejo seštevek bolnikov, ki so prešli s placeba na infliksimab, in tiste bolnike na infliksimabu, ki so jih vključili v odprt podaljšek študije.
Package leaflet: Information for the user Remsima 120 mg solution for injection in pre-filled syringe infliximab 
Navodilo za uporabo Remsima 120 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku infliksimab
Infliximab has been associated with systemic injection reactions, anaphylactic shock and delayed hypersensitivity reactions (see section 4.8). 
anafilaktičnim šokom in poznimi preobčutljivostnimi reakcijami (glejte poglavje 4.8).
‘Re-administration' below and section 4.4). 
T (glejte poglavj 4.8).
Please follow these steps: 
Prosimo, da sledite naslednjim korakom:
The following dosing table indicates what volume to administer depending on the weight of the dog: 
Naslednja tabela za odmerjanje prikazuje, kakšen volumen je treba dati v odvisnosti od teže psa:
The active substance in Rheumocam is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) 37/2010: 
Učinkovina zdravila Rheumocam je dovoljena učinkovina, kot je navedena v tabeli 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št. 37/2010:
Once in place the insert will not need to be removed 
Ko v mestu vložek ne bo treba odstraniti
To ensure correct dosage, body weight should be determined as accurately as possible to avoid underdosing or overdosing. 
Da bi zagotovili pravilno odmerjanje, telesne teže, je treba telesno težo določiti čim bolj natančno, da bi se izognili prenizkemu ali previsokemu odmerjanju.
Dose scheme for the maintenance dose: 
Shema odmerjanja za vzdrževalni odmerka:
This product is only for use in horses weighing between 500 and 600 kg. 
Ta izdelek je samo za uporabo pri konjih, ki tehtajo med 500 in 600 kg .
Date of last renewal: 18/12/2012. 
Datum podaljšanja dovoljenja za promet: 18/12/2012.
Shelf life after incorporation into muesli feed: use immediately. 
Rok uporabnosti po vključitvi v müsli krme: uporabite takoj.
Push the plunger until all contents of the syringe have been dispensed onto the food. 
Potiskajte bat, dokler niso vsi Vsebina brizge odpravijo na hrano
Date of first authorisation: 10/01/2008 Date of last renewal: 18/12/2012 
Datum pridobitve dovoljenja za promet: 10/01/2008 Datum zadnjega podaljšanja dovoljenja za promet: 18/12/2012
Česká republika Orion OYJ Zelený pruh 95/97, 140 00, Praha, ČR 
Orion OYJ Zelený pruh 95/97, 140 00, Praha, ČR
Non-infectious locomotor disorders. 
Neinfekcijske lokomotorne motnje
Paper foil sachets (paper/PE/alu/PE) containing 1.5 g granules per sachet in a cardboard box with 100 sachets. 
Vrečke papir folije (papir/PE/alu/PE), ki vsebuje 1,5 g zrnca na vrečko v kartonasti škatli s 100 vrečk .
Rheumocam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily. 
Žvečljivo tablete Rheumocam lahko dajemo s hrano ali brez nje, imajo dodano aromo in jih večina psov, vzame prostovoljno.
For example, a horse weighing 400 kg will receive 16 ml of Rheumocam, a horse weighing 500 kg will receive 20 ml of Rheumocam, and a horse weighing 600 kg will receive 24 ml of Rheumocam. 
Na primer, konj, ki tehta 400 kg, bo prejel 16 ml Rheumocama, konj, ki tehta 500 kg, bo prejel 20 ml Rheumocama in konj, ki tehta 600 kg, bo prejel 24 ml za Rheumocama.
Dose scheme for the maintenance dose: Body weight (kg) 
Shema odmerjanja za vzdrževalni odmerek: Telesna teže (kg)
Turn the bottle/syringe the right way up and with a twisting movement separate the syringe from the bottle. 
Obrnite plastenko / brizga pravo pot navzgor in z rotacijo ločite brizgo iz steklenice.
Before using Rheumocam for the very first time ensure that you have the bottle, circular plastic insert and syringe. 
Rheumocam za zelo prvič, da boste imeli steklenice, plastični vložek krožno in brizgo
Body weight (kg) 
Telesna teže (kg)
The product should be added to 250 g of muesli feed, prior to feeding. 
dodati 250 g müsli krme pred hranjenjem.
The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs, although quantitatively there are differences. 
Presnavljanje je kakovostno pri podganah, mini prašičih, ljudeh, govedih in prašičih podobno, količinsko pa se razlikuje.
This is equivalent to 1 ml of Rheumocam per 25 kg body weight of horse. 
To je enakovredno 1 ml Rheumocama na 25 kg telesne teže konja.
Acute respiratory infection. 
Akutne okužbe dihal
The major metabolites found in all species were the 5-hydroxyand 5-carboxy- metabolites and the oxalyl- metabolite. 
Poglavitni presnovki, ki so jih odkrili pri vseh vrstah, so 5-hidroksi- in 5karboksi-presnovki ter oksalil-presnovek.
This veterinary medicinal product does not require any special storage conditions. 
To zdravilo za uporabo v veterinarski medicini ne zahteva nobenih posebnih navodil za shranjevanje.
Replace the cap on the bottle and shake it well. 
Zamenjajte pokrovček na steklenico in jo dobro pretresite.
Turn the bottle with the syringe in place upside down and slowly withdraw the plunger until the required dose is evident. 
Obrnite plastenko z brizgo v kraju glavo in počasi umakne bat, dokler zahtevani odmerek je očitna.
For the first day, twice the maintenance dosage will be required. 
Prvi dan zdravljenja je potreben dvojni vzdrževalni odmerek.
42, 100 or 200 ml polyethylene terephthalate (PET) bottle with a tamper resistant child proof closure, and a 15 ml HDPE bottle with a tamper resistant child proof closure, and two polypropylene measuring syringes: one for small dogs (up to 20 kg) and one for bigger dogs (up to 60 kg). 
42, 100 ali 200 ml plastenka iz polietilen tereftalata (PET) z za otroke varno zaporko in 15 ml plastenka iz HDPE z za otroke varno zaporko, ter dve merilni brizgi iz polipropilena: ena za majhne pse (do 20 kg) in ena za večje pse (do 60kg).
BN {number} 
{VRSTA/TIP}
Puerperal septicaemia and toxaemia (MMA syndrome) with antibiotic therapy. 
Puerperalna septikemija in toksemija (sindrom MMA), ob antibiotičnem zdravljenju
Take care of accurate dosing, use of appropriate dosing devise and estimation of body weight. 
Poskrbite za natančno odmerjanje, uporabo ustrezne priprave za odmerjanje, in oceno telesne teže.
For dogs weighing less than 4 kg the use of Rheumocam oral suspension for dogs is recommended. 
Za pse z manjšo telesno teže od 4 kg priporočamo uporabo peroralne suspenzije za pse Rheumocam.
Place the circular plastic insert into the neck of the bottle and push down until securely in place. 
Postavite krožne plastični vložek v vrat steklenice in ga potisnite navzdol, dokler se trdno.
Maintenance dosage (ml) 
Vzdrževalni odmerek (ml)
Treatment of piglets with Rheumocam before castration reduces post-operative pain. 
Zdravljenje pujskov z zdravilom Rheumocam pred kastracijo blaži postoperativno bolečino.
Bottle (HDPE) 
OVOJNINAH Plastenka (HDPE)
{Label for 100 ml vials} 
{Nalepka za 100 ml viale}
Each bottle is packed in a cardboard box with a 1 ml measuring syringe (barrel in polypropylene and plunger/piston in high density polyethylene). 
Vsaka steklenica je pakirana v kartonsko škatlo z eno ml merilno brizgo (sodček v polipropilenu in bat
21% of the recovered dose is eliminated in urine (2% as unchanged meloxicam, 19% as metabolites) and 79% in the faeces (49% as unchanged meloxicam, 30% as metabolites). 
Enaindvajset odstokov prestreţenega odmerka se odstrani iz telesa z urinom (2 % v obliki nespremenjenega meloksikama, 19 % v obliki presnovkov), 79 % pa z blatom (49 % v obliki nespremenjenega meloksikama, 30 % v obliki presnovkov).
Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal. 
Žvečljivo tableto lahko razpolovimo in tako odmerek natančno prilagodimo telesni teže živali.
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
- zelo redki (manj kot 1 od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example, at the time of induction of anaesthesia. 
Lajšanje pooperativne bolečine (v 24-urnem obdobju): enkratna intravenska ali podkoţna injekcija pred operacijo, na primer ob indukciji anestezije.
The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 
Prisotnost presnovkov matične spojine v urinu in blatu, ne pa v plazmi, kaţe na hitro izločanje.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product. 
Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben ali pa, ne spadajo v področje uporabe
When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded. 
Kadar dajemo nesteroidna protivnetna zdravila sočasno z anestezijo, ni moţno izključiti tveganja škodljivih učinkov na ledvično delovanje.
Dosage for each species: 
Odmerjanje za vsako živalsko vrsto.
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example, at the time of induction of anaesthesia. 
Lajšanje pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva: nkratna podkoţna injekcija pred operacijo, na primer ob indukciji anestezije.
Shelf-life of the veterinary medicinal product as packaged for sale: 4 years Shelf-life after first opening the immediate packaging: 28 days 
Rok uporabnosti zdravila v ovojnini za prodajo: 4 leta Rok uporabnosti po prvem odpiranju stične ovojnine: 28 dni
- Ethanol (96%) - Poloxamer 188 - Macrogol 400 - Glycine - Disodium edetate - Sodium hydroxide - Hydrochloric acid, concentrated - Meglumine - Water for injections 
- etanol 96-odstotni - poloksamer 188 - makrogol 400 - glicin - dinatrijev edetat - natrijev hidroksid - klorovodikova kislina - meglumin - voda za injekcije
Pack size: 100 sachets. 
Velikost pakiranja: 100 vrečk.
Take off the bottle cap and attach the dosing syringe to the bottle by gently pushing the end into the hole. 
Snemite pokrovček stekleničke in pritrdite brizgo na steklenici, ki jih previdno pritisnete v luknjo .
Elimination Meloxicam is eliminated with a half-life of 26 hours after subcutaneous injection in young cattle. 
Razpolovna doba izločanja meloksikama je po podkožni injekciji pri mladem govedu 26 ur.
Date of first authorisation: 10/01/2008. 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 10/01/2008.
For Rheumocam 20 mg/ml solution for injection for cattle, pigs and horses and Rheumocam 5 mg/ml solution for injection for cats and dogs and Rheumocam 5 mg/ml solution for injection for cattle and pigs only: 
Samo za Rheumocam 20 mg/ml, raztopina za injiciranje za govedo, prašiče in konje in Rheumocam 5 mg/ml, raztopina za injiciranje za pse in mačke, in Rheumocam 5 mg/ml, raztopina za injiciranje za govedo in prašiče:
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought. 
Če se pojavijo neţeleni učinki, je treba zdravljenje prekiniti in se posvetovati z veterinarjem.
Cattle (calves and young cattle) and pigs 
Govedo (teleta in mlado govedo) in prašiči.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 µg/ml in dogs and 1.1 μg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively. 
Meloksikam je po podkoţnem dajanju v celoti biološko uporaben in doseţe največjo srednjo koncentracijo v plazmi, ki je 0,73 μg/ml pri psih in 1,1 μg/ml pri mačkah, pribliţno 2,5 ure oz. 1,5 ure po dajanju.
Do not use in dogs less than 6 weeks of age or less than 4 kg body weight. 
Ne uporabite pri psih, mlajših od 6 tednov ali z manjšo telesno teže od 4 kg.
Meloxicam: 
meloksikam:
Do not use in case of hypersensitivity to the active substance or to any of the excipients. 
Ne uporabite v primeru preobčutljivosti na zdravilno učinkovino ali katero koli pomoţno snov.
One sachet contains: 330 mg of meloxicam. 
Vsaka vrečka vsebuje: 330 mg meloksikama.
Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. 
Meloksikam je nesteroidna protivnetna učinkovina (NSAID) iz skupine oksikamov, ki zavira sintezo prostaglandinov in tako deluje protivnetno, analgetično, antieksudativno in antipiretično.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). 
4.7 Uporaba v obdobju brejosti, laktacije ali valjenja Varnost zdravila v obdobju brejostji in laktacije ni bila ugotovljena (glejte poglavje 4.3).
Pale-yellow, single-scored, chewable tablets. 
Žvečlijive tablete Svetlo rumene, žvečlijive tablete z zarezo na eni strani.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg. 
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri konjih ki tehtajo med 500 in 600 kg .
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 
Našteti neželeni učinki so najpogostejši prvi teden zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
Each sachet contains one dose for a horse weighing between 500 and 600 kg and the dose must not be divided into smaller doses. 
Ena vrečka vsebuje en odmerek za konja, ki tehtajo med 500 in 600 kg in odmerka ne sme biti razdeljen na manjše doze .
Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively. 
En žvečljiva tableta vsebuje 1 mg ali 2,5 mg meloksikama, kar ustreza dnevnemu vzdrževalnemu odmerku za psa s telesno teže 10 kg oziroma 25 kg.
Honey flavoured, white to off-white viscous oral suspension. 
Bele do umazano bele barve, z aromo medu, viskozna peroralna suspenzija
Musculo-skeletal disorders: single subcutaneous injection. 
Mišično-skeletna obolenja: enkratna podkoţna injekcija.
In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. 
V zelo redkih primerih so poročali o hemoragični diareji, bruhanju krvi (hematemeza) , gastro-intestinalnih ulkusih in povišani vrednosti jetrnih encimov.
White high density polyethylene bottle containing 10 ml or 15 ml with a tamper proof child resistant closure. 
Bela polietilenska plastenka z visoko gostoto, ki vsebuje 10 ml ali 15 ml za otroke varnim zapiralom.
The suspension can be given using the Rheumocam measuring syringe provided in the package. 
Suspenzijo lahko dajemo s priloženo merilno brizgo za zdravilo Rheumocam.
Oral suspension to be administered at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days. 
Peroralna suspenzija, ki jo dajemo v odmerkih po 0,6 mg/kg telesne teže, enkrat na dan, do 14 dni.
Diarrhoea in calves of over one week of age and young, non-lactating cattle. 
Driska pri teletih, starejših od enega tedna in mlademu govedu, ki ni v obdobju laktacije
The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). 
Brizga je oblikovana tako, da se prilega plastenki in ima merilno skalo z oznakami telesne težev kilogramih, ki ustrezajo vzdrževalnemu odmerku (0,1 mg meloksikama na kilogram telesne teže).
Horses. 
Konji .
Ireland. 
IRSKA.